Abstract 5528
Background
Amplifications in FGFR1are a potential target to therapy with FGFR inhibitors in squamous cell carcinoma NSCLC (SqCC). Recent insights in other entities demonstrate that the efficacy of these inhibitors is not limited to FGFR1 but affects the whole receptor family. We set out this analysis to identify NSCLC patients with mutations in FGFR2 and/or FGFR3 and to describe clinical and genomic characteristics.
Methods
Within the Network Genomic Medicine Lung Cancer (NGM), all stage IV patients underwent genomic testing using a gene panel consistent of 17 potential oncogenes. The panel was implemented in 2015, and data cut-off for this analysis was July 2018. The panel focuses on point mutations or deletions, i. e., rearrangements or copy-number aberrations were not detectable.
Results
Of 6000 patients analyzed, 26 (0.4%) had an FGFR2 mutation and 21 (0.4%) an FGFR3 mutation. 95% of the detected mutations have not been reported so far. Clinically, both subgroups differed from each other, most strikingly in the clinical presentation: The vast majority of FGFR2 mutations were detected in non-SqCC (76.9%), whereas FGFR3 mutations occurred more commonly in SqCC (57.1%). In the FGFR2 group, more female patients were affected (57.7%), contrasting 71.4% male patients in the FGFR3 group. KRAS mutations co-occurred more frequently in the FGFR2 group (23.1% vs 9.5%) and PIK3CA mutations more frequently in the FGFR3 group (19.0% vs 7.7%). For both groups, most mutations did not affect the kinase domain. Patients with FGFR2 mutation seem to have a favorable outcome as compared to FGFR3 patients (median overall survival not reached vs 8.0 months), but follow-up is still immature (p = 0.201).
Conclusions
Patients with FGFR2 and FGFR3 mutations represent two vastly different subgroups of NSCLC patients. Both mutations are not limited to SqCC and seem to have different prognoses for the outcome of the patients. Further work on the characterization of the different mutations is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Network Genomic Medicine (NGM) Lung Cancer.
Funding
Has not received any funding.
Disclosure
M. Scheffler: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Advisory / Consultancy, Travel / Accommodation / Expenses: Mediolanum Biosciences; Honoraria (self): Roche; Advisory / Consultancy: Novartis; Advisory / Consultancy: Takeda; Advisory / Consultancy: BMS. A. Kron: Advisory / Consultancy: BMS; Advisory / Consultancy: AbbVie; Advisory / Consultancy: Novartis. D.S.Y. Abdulla: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Travel / Accommodation / Expenses: AbbVie. R. Riedel: Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Advisory / Consultancy, Travel / Accommodation / Expenses: Lilly. S. Michels: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Roche; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim. R.N. Fischer: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Travel / Accommodation / Expenses: Boehringer Ingelheim. S. Merkelbach-Bruse: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Novartis. R. Büttner: Honoraria (self): Pfizer; Honoraria (self): Novartis. L. Nogova: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Celgene; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: MSD. J. Wolf: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AbbVie; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Chugai; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Ignyta; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche. All other authors have declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract